Bright Angel Therapeutics Announces New Funding to Advance Therapies for Invasive Fungal Infections

Ontario Industry Updates
Written By Guest User

Bright Angel Therapeutics, a biotechnology company focused on developing novel antifungal drugs, announced an extension to their seed financing round, adding funding that will enable continued advancement of their lead program targeting invasive and drug-resistant fungal infections.

Guest User
Previous

Flosonics Medical Counts Down to Product Launch in Early 2020
Next

Apply for Ontario Health Trade Mission to Korea and Japan